Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OLIGORESIST
2023-505024-62-01Phase 2Authorised
- Sponsor
- Instituto de Investigación en Oncología Radioterápica
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of enzalutamide and abiraterone in castration-resistant prostate cancer (CRPC), sponsored by Instituto de Investigación en Oncología Radioterápica. Primary endpoint: Radiological progression-free survival. Planned start Oct 2023; status: authorised.
02
Drugs
enzalutamideabiraterone
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on 2023-505024-62-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505024-62-01.